Ferrocene-Mediated Proton-Coupled Electron Transfer in a Series of Ferrocifen-Type Breast-Cancer Drug Candidates
about
Redox activation of metal-based prodrugs as a strategy for drug deliverySimilar Biological Activities of Two Isostructural Ruthenium and Osmium ComplexesSynthesis and antiproliferative activity of hydroxyferrocifen hybrids against triple-negative breast cancer cells.Bis-arylidene oxindoles as anti-breast-cancer agents acting via the estrogen receptor.Cytotoxic and antioxidant properties of active principals isolated from water hyacinth against four cancer cells linesCytotoxicity of Pyrazine-Based Cyclometalated (C^Npz^C)Au(III) Carbene Complexes: Impact of the Nature of the Ancillary Ligand on the Biological Properties.A tandem mass spectrometric investigation of N-(3-ferrocenyl-2-naphthoyl) dipeptide ethyl esters and N-(6-ferrocenyl-2-naphthoyl) dipeptide ethyl esters.Heterometallic platinum(II) compounds with β-aminoethylferrocenes: synthesis, electrochemical behaviour and anticancer activity.Organometallic anticancer compoundsOxidative metabolism of ferrocene analogues of tamoxifen: characterization and antiproliferative activities of the metabolites.Ferrocenyl Quinone Methide-Thiol Adducts as New Antiproliferative Agents: Synthesis, Metabolic Formation from Ferrociphenols, and Oxidative Transformation.New trends for metal complexes with anticancer activityBioorganometallic chemistry--from teaching paradigms to medicinal applications.Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs.Metallocenes as Target Specific Drugs for Cancer Treatment.Ferrocifen type anti cancer drugs.Quantitative analyses of ROS and RNS production in breast cancer cell lines incubated with ferrocifens.Efficient new constructs against triple negative breast cancer cells: synthesis and preliminary biological study of ferrocifen-SAHA hybrids and related species.Nanotherapeutic systems for local treatment of brain tumors.Ferrocenyl catechols: synthesis, oxidation chemistry and anti-proliferative effects on MDA-MB-231 breast cancer cells.Ferrocenyl quinone methides as strong antiproliferative agents: formation by metabolic and chemical oxidation of ferrocenyl phenols.Structural and biological investigation of ferrocene-substituted 3-methylidene-1,3-dihydro-2H-indol-2-ones.Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and PromisesROS-activated anticancer prodrugs: a new strategy for tumor-specific damage.Os2 -Os4 Switch Controls DNA Knotting and Anticancer ActivityAntimicrobial activity of organometallic isonicotinyl and pyrazinyl ferrocenyl-derived complexes.The ferroquine antimalarial conundrum: redox activation and reinvasion inhibition.Antioxidative activity of ferrocenes bearing 2,6-di-tert-butylphenol moieties.The synthesis and structures of 1,1'-bis(sulfonyl)ferrocene derivatives.Controlling Platinum, Ruthenium and Osmium Reactivity for Anticancer Drug Design.Deciphering the activation sequence of ferrociphenol anticancer drug candidates.Vesicular disruption of lysosomal targeting organometallic polyarginine bioconjugates.Adsorption of diferrocenylacetylene on Au(111) studied by scanning tunneling microscopy.Nucleoside analogues with a 1,3-diene-Fe(CO)3 substructure: stereoselective synthesis, configurational assignment, and apoptosis-inducing activity.Remarkable anticancer activity of ferrocenyl-terpyridine platinum(ii) complexes in visible light with low dark toxicity.Synthesis and structure analysis of ferrocene-containing pseudopeptides.Palladacycles of sulfated and selenated Schiff bases of ferrocene-carboxaldehyde as catalysts for O-arylation and Suzuki-Miyaura coupling.New 1,1'-Ferrocene Bis(sulfonyl) Reagents.Molecular mechanism of action of 2-ferrocenyl-1,1-diphenylbut-1-ene on HL-60 leukemia cells.1H-1,2,3-triazole-tethered uracil-ferrocene and uracil-ferrocenylchalcone conjugates: Synthesis and antitubercular evaluation.
P2860
Q27025736-1C4680C3-1627-4E68-BFC4-1A0B9EFFD824Q27650404-5E6C0E5B-A453-4DB2-9F26-F6ED239E582DQ30683354-4C12E448-36EB-4904-939E-9989F314B6ADQ30746277-75AEE53B-07E0-470C-B8B9-AFEF3AA4C1F8Q30860272-989AF2E9-5231-4FFB-8B96-B467C2CBC64CQ33696556-152F55C8-CD7A-4F51-B920-557E1DD3DDF1Q34018159-BC08623F-DAEE-46CE-8A3F-E4FB16E9E1D9Q34057015-B8434763-5058-40A4-B11F-10DB60326C70Q34476685-01C5CC00-08D1-40E3-8ECA-5507B72D47D7Q35604815-325E4A0C-D069-46E0-9635-DE15D9E07BD0Q36045117-1EDB70C7-7EFE-4C42-A82A-DE3E2E60AC29Q37044080-056072E0-9EA9-4FD2-830B-F2A8B43490E3Q37377528-906B023D-B7AA-43AD-91C5-EA913E44C8EAQ37603642-AACEB12C-CAB3-4173-8909-ED4E99914728Q38062521-F4CFD2B8-D6AE-4FA9-B5BA-CCADC8518FC6Q38612680-7A4F0EBB-7955-4053-A24F-EC1B92B9642FQ38997703-25126419-3D5C-4D78-991D-0F4C7D0CE9BBQ39096632-EFC0CBC3-C192-492E-9449-0D1A2692FE33Q39330269-785E20B6-EFF8-4F01-8058-BCB62C0FFEFCQ39346477-9920EF54-38FE-424A-BBEF-716A49567F05Q39781648-9903970E-BFEB-46C9-A484-8C1A822BC5C1Q39890365-65330E51-4382-4C5C-94FD-9FCA34F84B5AQ41664067-AEAADD2E-80C2-4887-BB79-321768DEFA65Q41815659-0E0927E3-C664-4FA3-9DC0-15036DC8BB5BQ41911879-347E1F82-D1C0-4FA0-8017-1426D21112E0Q41912333-26FD7FCD-C601-4C3B-BD4E-5EE0C11B465FQ41925428-343FCEC2-48A2-4BBA-A691-8108D6A6AF24Q42113294-05856D11-48AA-4058-9181-33289F3AB11EQ42277863-75686F37-43F5-448D-9DBB-1648584B19C0Q42576712-25B13A92-1C56-4A14-A25D-AC7D10619625Q44853406-9F1AD2AB-7F98-48F8-BFF9-B8BF2A238763Q46783979-B411BCFD-9EB1-4D84-8D5C-61583CDF4F9BQ46833976-2A4BFC9A-1088-47BC-A9DE-2780037AED9DQ46881235-D1CF6F67-45B6-4916-9160-1941467A61B0Q46979535-179BAF81-5436-44DF-A09D-1891717BBFAAQ48147716-900BD550-3FE7-413C-9302-F39FDF642C6CQ48291401-C4154658-F4D1-4FAC-A2CC-105F9BF7F683Q49712226-E69D69A9-31B5-45DE-B46A-976D0068ECA1Q51060992-2505A8C8-0630-4949-AF1C-844BCEF3C62AQ51098218-BAC53E7A-9CFE-447E-82F6-A0AB45336790
P2860
Ferrocene-Mediated Proton-Coupled Electron Transfer in a Series of Ferrocifen-Type Breast-Cancer Drug Candidates
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2006
@uk
name
Ferrocene-Mediated Proton-Coup ...... Breast-Cancer Drug Candidates
@en
Ferrocene-Mediated Proton-Coup ...... Breast-Cancer Drug Candidates
@nl
type
label
Ferrocene-Mediated Proton-Coup ...... Breast-Cancer Drug Candidates
@en
Ferrocene-Mediated Proton-Coup ...... Breast-Cancer Drug Candidates
@nl
prefLabel
Ferrocene-Mediated Proton-Coup ...... Breast-Cancer Drug Candidates
@en
Ferrocene-Mediated Proton-Coup ...... Breast-Cancer Drug Candidates
@nl
P50
P356
P1476
Ferrocene-Mediated Proton-Coup ...... Breast-Cancer Drug Candidates
@en
P2093
Anne Vessières
P304
P356
10.1002/ANIE.200502925
P407
P577
2006-01-01T00:00:00Z